[Form 4] PLUS THERAPEUTICS, Inc. Insider Trading Activity
Robert P. Lenk, a director of PLUS THERAPEUTICS, Inc. (PSTV), was granted stock options on 08/13/2025. The Form 4 reports acquisition of 297,794 stock options with an exercise price of $0.5744 per share. The filing states the options vest monthly over 12 months from the grant date and vest in full upon the issuer's 2026 Annual Stockholder Meeting, subject to continued service. The Form 4 shows the reporting person holds 297,794 underlying shares following the transaction and is filed by one reporting person. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Robert P. Lenk, amministratore di PLUS THERAPEUTICS, Inc. (PSTV), ha ricevuto opzioni su azioni in data 13/08/2025. Il Form 4 segnala l'acquisizione di 297.794 opzioni con un prezzo di esercizio di $0.5744 per azione. La comunicazione indica che le opzioni maturano mensilmente nell'arco di 12 mesi dalla data di concessione e maturano interamente alla riunione annuale degli azionisti del 2026 della societ脿 emittente, subordinatamente al proseguimento del servizio. Il Form 4 mostra che la persona che effettua la segnalazione detiene 297.794 azioni sottostanti dopo la transazione ed 猫 presentato da un unico dichiarante. Il documento 猫 firmato da un procuratore delegato per conto del dichiarante.
Robert P. Lenk, director de PLUS THERAPEUTICS, Inc. (PSTV), recibi贸 opciones sobre acciones el 13/08/2025. El Form 4 informa la adquisici贸n de 297.794 opciones con un precio de ejercicio de $0.5744 por acci贸n. La presentaci贸n indica que las opciones se adquieren mensualmente durante 12 meses desde la fecha de concesi贸n y se adquieren por completo en la Junta Anual de Accionistas 2026 del emisor, sujeto a la continuidad del servicio. El Form 4 muestra que la persona informante posee 297.794 acciones subyacentes tras la transacci贸n y que la presentaci贸n la realiza una sola persona informante. El documento est谩 firmado por un apoderado en nombre del informante.
PLUS THERAPEUTICS, Inc.(PSTV) 鞚挫偓 搿滊矂韸� P. 霠岉伂電� 2025-08-13鞐� 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. Form 4電� 頄夓偓臧�瓴� 欤茧嫻 $0.5744鞚� 297,794欤� 鞓奠厴 旆摑鞚� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞓奠厴鞚� 攵�鞐澕搿滊秬韯� 12臧滌洈 霃欖晥 毵れ洈 鞚茧秬鞌� 氩犾姢韺呺悩氅�, 氚滍枆須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 瓿勳啀 攴茧頃橂姅 瓴冹潉 鞝勳牅搿� 鞝勳暋 氩犾姢韺呺悳雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 鞁犼碃鞚胳澊 鞚措矆 瓯半灅 頉� 297,794 旮办磮欤检嫕鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 頃� 氇呾潣 鞁犼碃鞚胳澊 鞝滌稖頄堧嫟瓿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 鞁犼碃鞚胳潉 雽�鞁犿暅 鞙勳瀯 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Robert P. Lenk, administrateur de PLUS THERAPEUTICS, Inc. (PSTV), s'est vu accorder des options sur actions le 13/08/2025. Le Form 4 rapporte l'acquisition de 297鈥�794 options au prix d'exercice de $0.5744 par action. Le d茅p么t pr茅cise que les options acqui猫rent des droits mensuellement sur 12 mois 脿 compter de la date d'octroi et deviennent enti猫rement acquises lors de l'assembl茅e g茅n茅rale annuelle des actionnaires 2026 de l'茅metteur, sous r茅serve de la continuit茅 du service. Le Form 4 indique que la personne d茅clarant d茅tient 297鈥�794 actions sous-jacentes apr猫s la transaction et que la d茅claration est faite par une seule personne d茅clarante. Le document est sign茅 par un mandataire au nom du d茅clarant.
Robert P. Lenk, Direktor von PLUS THERAPEUTICS, Inc. (PSTV), wurde am 13.08.2025 Aktienoptionen gew盲hrt. Das Form 4 meldet den Erwerb von 297.794 Optionen mit einem Aus眉bungspreis von $0.5744 je Aktie. Die Einreichung besagt, dass die Optionen monatlich 眉ber 12 Monate ab dem Gew盲hrungsdatum vesten und bei der ordentlichen Hauptversammlung des Emittenten 2026 vollst盲ndig vesten, vorbehaltlich fortgesetzter Dienstleistung. Das Form 4 weist aus, dass die meldende Person nach der Transaktion 297.794 zugrunde liegende Aktien h盲lt und dass die Meldung von einer meldenden Person eingereicht wurde. Das Dokument ist von einem bevollm盲chtigten Anwalt im Namen der meldenden Person unterschrieben.
- Retention-aligned vesting: Options vest monthly over 12 months and fully at the 2026 Annual Stockholder Meeting, aligning director incentives with the company.
- Clear disclosure: Form 4 provides explicit details on number of options, exercise price, and vesting terms.
- Potential dilution: Grant of 297,794 options will increase potential shares outstanding if exercised.
- Limited context: Filing does not state total shares outstanding or grant date definition needed to assess relative materiality.
Insights
TL;DR: Director received a sizable option grant at a low exercise price, which is a routine retention incentive with modest immediate market impact.
The grant of 297,794 options at $0.5744 is material in absolute share count but must be viewed relative to the company's total shares outstanding to assess dilution; that metric is not provided in the filing. The vesting schedule鈥攎onthly over 12 months and full vesting at the 2026 Annual Meeting鈥攁ligns incentives to retain the director through next year. No cash proceeds or dispositions are reported and the transaction code indicates acquisition. The filing contains no additional financial performance data or changes to existing holdings beyond this grant.
TL;DR: Standard director option grant with time-based vesting; disclosure complies with Section 16 reporting requirements.
The Form 4 properly discloses beneficial ownership change for a director via an option award and includes an explanation of vesting terms. The use of an attorney-in-fact signature is disclosed. The filing does not indicate any performance-based vesting conditions or related-party transactions beyond the director relationship. For governance review, the key missing context is the grant date definition and the company's equity pool size, which are not stated in this filing.
Robert P. Lenk, amministratore di PLUS THERAPEUTICS, Inc. (PSTV), ha ricevuto opzioni su azioni in data 13/08/2025. Il Form 4 segnala l'acquisizione di 297.794 opzioni con un prezzo di esercizio di $0.5744 per azione. La comunicazione indica che le opzioni maturano mensilmente nell'arco di 12 mesi dalla data di concessione e maturano interamente alla riunione annuale degli azionisti del 2026 della societ脿 emittente, subordinatamente al proseguimento del servizio. Il Form 4 mostra che la persona che effettua la segnalazione detiene 297.794 azioni sottostanti dopo la transazione ed 猫 presentato da un unico dichiarante. Il documento 猫 firmato da un procuratore delegato per conto del dichiarante.
Robert P. Lenk, director de PLUS THERAPEUTICS, Inc. (PSTV), recibi贸 opciones sobre acciones el 13/08/2025. El Form 4 informa la adquisici贸n de 297.794 opciones con un precio de ejercicio de $0.5744 por acci贸n. La presentaci贸n indica que las opciones se adquieren mensualmente durante 12 meses desde la fecha de concesi贸n y se adquieren por completo en la Junta Anual de Accionistas 2026 del emisor, sujeto a la continuidad del servicio. El Form 4 muestra que la persona informante posee 297.794 acciones subyacentes tras la transacci贸n y que la presentaci贸n la realiza una sola persona informante. El documento est谩 firmado por un apoderado en nombre del informante.
PLUS THERAPEUTICS, Inc.(PSTV) 鞚挫偓 搿滊矂韸� P. 霠岉伂電� 2025-08-13鞐� 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. Form 4電� 頄夓偓臧�瓴� 欤茧嫻 $0.5744鞚� 297,794欤� 鞓奠厴 旆摑鞚� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 鞓奠厴鞚� 攵�鞐澕搿滊秬韯� 12臧滌洈 霃欖晥 毵れ洈 鞚茧秬鞌� 氩犾姢韺呺悩氅�, 氚滍枆須岇偓鞚� 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 瓿勳啀 攴茧頃橂姅 瓴冹潉 鞝勳牅搿� 鞝勳暋 氩犾姢韺呺悳雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4鞐愲姅 頃措嫻 鞁犼碃鞚胳澊 鞚措矆 瓯半灅 頉� 297,794 旮办磮欤检嫕鞚� 氤挫湢頃橁碃 鞛堨溂氅�, 頃� 氇呾潣 鞁犼碃鞚胳澊 鞝滌稖頄堧嫟瓿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟. 靹滊電� 鞁犼碃鞚胳潉 雽�鞁犿暅 鞙勳瀯 氤�順胳偓臧� 靹滊獏頄堨姷雼堧嫟.
Robert P. Lenk, administrateur de PLUS THERAPEUTICS, Inc. (PSTV), s'est vu accorder des options sur actions le 13/08/2025. Le Form 4 rapporte l'acquisition de 297鈥�794 options au prix d'exercice de $0.5744 par action. Le d茅p么t pr茅cise que les options acqui猫rent des droits mensuellement sur 12 mois 脿 compter de la date d'octroi et deviennent enti猫rement acquises lors de l'assembl茅e g茅n茅rale annuelle des actionnaires 2026 de l'茅metteur, sous r茅serve de la continuit茅 du service. Le Form 4 indique que la personne d茅clarant d茅tient 297鈥�794 actions sous-jacentes apr猫s la transaction et que la d茅claration est faite par une seule personne d茅clarante. Le document est sign茅 par un mandataire au nom du d茅clarant.
Robert P. Lenk, Direktor von PLUS THERAPEUTICS, Inc. (PSTV), wurde am 13.08.2025 Aktienoptionen gew盲hrt. Das Form 4 meldet den Erwerb von 297.794 Optionen mit einem Aus眉bungspreis von $0.5744 je Aktie. Die Einreichung besagt, dass die Optionen monatlich 眉ber 12 Monate ab dem Gew盲hrungsdatum vesten und bei der ordentlichen Hauptversammlung des Emittenten 2026 vollst盲ndig vesten, vorbehaltlich fortgesetzter Dienstleistung. Das Form 4 weist aus, dass die meldende Person nach der Transaktion 297.794 zugrunde liegende Aktien h盲lt und dass die Meldung von einer meldenden Person eingereicht wurde. Das Dokument ist von einem bevollm盲chtigten Anwalt im Namen der meldenden Person unterschrieben.
FAQ
What did PSTV director Robert P. Lenk acquire on 08/13/2025?
What are the vesting terms of the options reported for PSTV?
How many shares does the reporting person beneficially own after the transaction?
Who filed the Form 4 for Robert P. Lenk?
What is the exercise price of the options granted to the director?
